Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | Non-clear cell kidney cancer trial updates: CALYPSO and KEYNOTE-427

Tracy Rose • 15 Feb 2019
GU Cancers 2019
Genitourinary Cancer Kidney Cancer Durvalumab Pembrolizumab Savolitinib
CALYPSO KEYNOTE-427

Tracy Rose, MD, of UNC Health Care, Chapel Hill, NC, presents a detailed overview on the Phase II CALYPSO trial (NCT02819596) investigating the use of savolitinib and durvalumab in papillary renal cancer, and the Phase II KEYNOTE-427 study (NCT02853344) looking at the efficacy of pembrolizumab therapy in renal cell carcinoma (RCC). This video was recorded at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Tracy Rose

Tracy Rose: RCC highlights
1:21
Tracy Rose: RCC highlights
Tracy Rose • 13 Feb 2020
Kidney cancer: combining PARP inhibitors and immunotherapy
4:32
Kidney cancer: combining PARP inhibitors and immunotherapy
Tracy Rose • 13 Feb 2020
New tools for RCC treatment
1:16
New tools for RCC treatment
Tracy Rose • 14 Feb 2020
Effect of FGFR status on checkpoint inhibitor response in bladder cancer
2:53
Effect of FGFR status on checkpoint inhibitor response in bladder cancer
Tracy Rose • 15 Feb 2019

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals